Use of the PRO Onc Assay (Prometheus) to measure HER2 overexpression/activation in circulating tumor cells (CTCs) in women with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute (SCRI) trial.
John D. Hainsworth
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Patrick Brian Murphy
No relevant relationships to disclose
Ruth E. Lamar
No relevant relationships to disclose
Mythili Shastry
No relevant relationships to disclose
Lindsey H. Finney
No relevant relationships to disclose
Denise Aysel Yardley
Consultant or Advisory Role - Genentech (U)